Applications of protein arrays for small molecule drug discovery and characterization

Biotechnology and Genetic Engineering Reviews

Volumn 22, Issue 1, 2006, Pages 197-212

  Michaud, Gregory A ^a   Aelsalcius, Mich ^a   Zhou, Fang ^a   Papov, Vladimir V ^b   Merkel, Janie ^a   Murtha, Michael ^a   Predki, Paul ^a   Schweitzer, Barry ^a  

^a Invitrogen Corporation   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DISCOVERY; PROTEIN ARRAYS; SMALL-MOLECULE DRUGS;

PROTEINS;

ALPRAZOLAM; AMLODIPINE BESYLATE; ANASTROZOLE; CARBOXYLASE; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR KINASE; HORMONE RECEPTOR; IMATINIB; ION CHANNEL; LOSARTAN; METALLOPROTEINASE; OXIDOREDUCTASE; PHOSPHOPROTEIN PHOSPHATASE; PROPRANOLOL; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RANITIDINE; SERINE PROTEINASE; SUMATRIPTAN SUCCINATE; ZOLPIDEM TARTRATE;

BINDING AFFINITY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN TARGETING; REVIEW;

EID: 33645974884     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2006.10648071     Document Type: Article

References (40)

1. Anderson. M.E. and Siahaan. T.J. (2003). Targeting ICAM-l/LFA-l interaction for controlling autoimmune diseases:designing peptide and small molecule inhibitors. Peptides24, 487–501
2. Baggio, R., Carven. G.J., Chiulli, A., Palmer. M., Stern. L.J. and Arenas, J.E. (2005). Induced fit of an epitope peptide to a monoclonal antibody probed with a novel parallel surface plasmon resonance assay. Journal of Biological Chemistry280(6). 4188–4194
3. Booth. B. and Zemmel. R. (2003). Quest for the best. Nature Reviews in Drug Discovery2, 838–841
4. Calvert. P., Yao. K.S., Hamilton. T.C. and O’Dwyer, P.J. (1998). Clinical studies of reversal of drug resistance based on glutathione. Chemical Biological Interactions 111–112, 213–224
5. Chan. T.F., Carvalho. J., Riles. L. and Zheng. X.F. (2000). A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proceedings of the National Academy of Sciences of the United States of America97, 13227–13232
6. Chen. G.Y., Uttamchandani. M., Zhu. Q., Wang. G. and Yao. S.Q. (2003). Developing a strategy for activity-based detection of enzymes in a protein microarray. Chembiochemistry4, 336–339
7. Couzin, J. (2004). Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science306, 384–385
8. Davies. S.P., Reddv, H., Caivano. M. and Cohen. P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal351, 95–105
9. Dimasi, J.A., Hansen, R.W. and grabowski H.G. (2003). The price of innovation:new estimates of drug development costs. Journal of Health Economics22, 151–185
10. Fang, Y., Frutos, A.G. and Lahiri, J. (2002). Membrane protein microarrays. Journal of the American Chemical Society124, 2394–2395
11. Ge. H. (2000). UPA. a universal protein array system for quantitative detection of protein-protein. protein-DNA. protein-RNA, and protein-ligand interactions. Nucleic Acids Research28, e3.
12. Hall, D., A., Zhu. H., Zhu. X., Royce. T., Gerstein. M. and Snyder. M. (2004). Regulation of gene expression by a metabolic enzyme. Science306, 482–484
13. Hopkins, A.L. and Groom, C.R. (2002). The druggable genome. Nature Reviews in Drug discovery1, 727–730
14. Huang, J., Zhu, H., Haggarty, S.J. et al. (2004). Finding new components of the target of rapamycin (TOR) signalling network through chemical genetics and proteome chips. Proceedings of the National Academy of Sciences of the United States of America101, 16594–16599.
15. International Human Genome Sequencing Consortium (2004). Finishing the euchromatic sequence of the human genome. Nature431, 931–945
16. Jung, G.Y. and Stephanopoulos, G. (2004). A functional protein chip for pathway optimization and in vitro metabolic engineering. Science304, 428–431
17. Knezevic, V., Leethanakul, C., Bichsel, V.E. et al. (2001). Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics1, 1271–1278
18. Kubinyi. H. (2003). Drag research:myths, hype and reality. Nature Reviews in Drug Discovery2, 665–668
19. Li. Y., Liu. J. and Zhan, X. (2000). Tyrosine phosphorylation of cortactin is required for H202-mediated injury of human endothelial cells. Journal of Biological Chemistiy275, 37187–37193.
20. Lipinski. C.A., Lombardo, F., Dominy. B.W. and Feeney. P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews46, 3–26
21. MacBeath. G. and Schreiber. S.L. (2000). Printing proteins as microarrays for high-throughput function determination. Science289, 1760–1763.
22. Mamdani, M., Juurlink, D.N., Lee, D.S. et al. (2004). Cyclooxygenase-2 inhibitors versus non-selective, non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients:a population-based cohort study. Lancet363, 1751–1756
23. Manning. G., Whyte, D.B., Martinez. R., Hunter. T. and Sudarsanam. S. (2002). The protein kinase complement of the human genome. Science298, 1912–1934
24. Mattern, I., Koomagi.R. and Volm.M. (2002). Expression of drug resistance gene products during progression of lung carcinomas. Oncology Reproduction9, 1181–1184.
25. Michaud, G.A., Salcius, M., Zhou, F. et al. (2003). Analysing antibody specificity with whole proteome microarrays. Nature Biotechnology21, 1509–1512
26. Mirzabekov, A. and Kolchinsky, A. (2002). Emerging array-based technologies in proteomics. Current Opinion in Chemistry and Biology6, 70–75
27. Newman, J.R. and Keating, A.E. (2003). Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science300, 2097–2101
28. Noble. M.E., Endicott. J.A. and Johnson, L.N. (2004). Protein kinase inhibitors:insights into drug design from structure. Science303, 1800–1805.
29. Ota, T., Suzuki, Y., Nishikawa, T. et al. (2004). Complete sequencing and characterization of 21 243 full-length human cDNAs. Nature Genetics36, 40–45
30. Predki. P.F. (2004). Functional protein microarrays:ripe for discovery. Current Opinion in Chemistry and Biology8, 8–13
31. Pritchard, J.F., Jurima-Romet, M., Reimer, M.L., Mortimer, E., Rolfe, B. And Cayen, M.N. (2003). Making better drugs:decision gates in non-clinical drug development. Nature Reviews in Drug Discovery2, 542–553
32. Schweitzer. B., Predki. P. and Snyder. M. (2003). Microarrays to characterize protein interactions on a whole-protcome scale. Proteomics3, 2190–2199
33. Stout. T.J., Foster, P.G. and Matthews. D.J. (2004). High-throughput structural biology in drug discovery:protein kinases. Current Pharmaceutical Design10, 1069–1082
34. Takahashi I., Kobayashi.E., Asano, K., Yoshida, M. and Nakano, H. (I987). UCN-Oi, a selective inhibitor of protein kinase C from Streptomyces. Journal of Antibiotics (Tokyo)40, 1782–1784
35. Van DE Waterbeemd. H. and Gifford, E. (2003). ADMET in silico modelling:towards prediction paradise? Nature Reviews in Drug Discovery2, 192–204
36. Walters. W.P, and Namchuk, M. (2003). Designing screens:how to make your hits a hit. Nature Reviews in Drug Discovery2, 259–266
37. Weinberg, J.B. (2000). Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammalion. Immunologic Research22, 319–341
38. Yaffe, M.B. and Smerdon, S.J. (2004). The use of in vitro peptide-Iibrary screens in the analysis of phosphoserine/threonine-binding domain structure and function. Annual Review of Biophysics and Biomolecular Structure33, 225–244
39. Zhu, H. and Snyder, M. (2001). Protein arrays and microarrays. Current Opinion in Chemistry and Biology5, 40–45
40. Zhu, H., Bilgin, M., Bangham, R. et al, (2001). Global analysis of protein activities using proteome chips. Science293, 2101–2105.